NCT03268655

Brief Summary

Estimate the impact of a 6-week daily intake of 2000 mg of ginger extract on the composition of the gut microbiome using a randomized placebo-controlled double-blinded design, i.e. examine the change of microbiome over time within and between the subjects..

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
68

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Nov 2018

Geographic Reach
1 country

13 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 25, 2017

Completed
6 days until next milestone

First Posted

Study publicly available on registry

August 31, 2017

Completed
1.2 years until next milestone

Study Start

First participant enrolled

November 14, 2018

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 26, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 26, 2020

Completed
Last Updated

July 22, 2020

Status Verified

July 1, 2020

Enrollment Period

1.6 years

First QC Date

August 25, 2017

Last Update Submit

July 21, 2020

Conditions

Keywords

gingerolmicrobiomegutginger

Outcome Measures

Primary Outcomes (2)

  • Composition of the gut microbiome

    Fecal microbial diversity and the prevalence of specific taxa associated with colorectal cancer (e.g. Fusobacteria, butyrate producing bacteria) will be estimated at 6 weeks. The ginger-related changes in the prevalence of each taxon will be assessed individually and also combined into a microbiome index (the abundance of protective taxa will be included as a negative value).

    Baseline to 6 Weeks

  • Urine inflammatory biomarker

    Urinary metabolite of Prostaglandin E2 (ng/mg of creatinine) will be measured before and after treatment with ginger. Changes in inflammatory markers will be correlated to changes in the microbial diversity and the microbiome composition

    Baseline to 6 weeks

Secondary Outcomes (1)

  • Change in gut microbiome composition

    Baseline to 12 weeks

Study Arms (2)

Ginger extract

EXPERIMENTAL

Ginger extract, 2000 mg daily for 6 weeks, followed by 6 week washout.

Dietary Supplement: Ginger extract

Placebo

EXPERIMENTAL

Placebo, daily for 6 weeks, followed by 6 week washout.

Other: Placebo

Interventions

Ginger extractDIETARY_SUPPLEMENT

2000 mg ginger extract daily for 6 weeks, plus 6 weeks washout

Ginger extract
PlaceboOTHER

2000 mg ginger extract daily for 6 weeks, plus 6 weeks washout

Placebo

Eligibility Criteria

Age50 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Colorectal adenoma diagnosis

You may not qualify if:

  • Allergy or sensitivity to ginger
  • Active cancer
  • Unstable medical condition
  • Unstable diet or weight

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (13)

Mayo Clinic Cancer Center

Albert Lea, Minnesota, 56007, United States

Location

Mayo Clinic Cancer Center

Austin, Minnesota, 55912, United States

Location

Essentia Health - Deer River

Deer River, Minnesota, 56636, United States

Location

Essentia Health St Mary's - Detroit Lakes

Detroit Lakes, Minnesota, 56501, United States

Location

Essentia Health - Fosston Clinic

Fosston, Minnesota, 56542, United States

Location

Fairview Grand Itasca Clinic & Hospital

Grand Rapids, Minnesota, 55744, United States

Location

Fairview Range Medical Center

Hibbing, Minnesota, 55746, United States

Location

Mayo Clinic Cancer System

Mankato, Minnesota, 56001, United States

Location

Epidemiology Clinical Research Center

Minneapolis, Minnesota, 55415, United States

Location

Monticello Cancer Center

Monticello, Minnesota, 55362, United States

Location

Essentia Health - Park Rapids Clinic

Park Rapids, Minnesota, 56470, United States

Location

Fairview Northland Medical Center

Princeton, Minnesota, 55371, United States

Location

Essentia Health -Virgina Clinic

Virginia, Minnesota, 55792, United States

Location

MeSH Terms

Interventions

ginger extract

Study Officials

  • Anna Prizment, PhD, MPH

    University of Minnesota, Epidemiology and Community Health

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Masking Details
Double blind
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Model Details: Pilot. Double-blind placebo-controlled randomized trial
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 25, 2017

First Posted

August 31, 2017

Study Start

November 14, 2018

Primary Completion

June 26, 2020

Study Completion

June 26, 2020

Last Updated

July 22, 2020

Record last verified: 2020-07

Data Sharing

IPD Sharing
Will not share

The results of the study will be disseminated to various stakeholders through the publication of a manuscript in a peer-reviewed journal and through presentation at scientific meetings.

Locations